LaFayette, NY, June 20, 2016 – Ichor Therapeutics, Inc a biotech contract research firm specializing in age-related diseases, adds Dr. Bärbel Rohrer to their scientific advisory board. Dr. Rohrer will assist with the design and execution of pivotal animal studies for Ichor’s therapeutic candidates for age-related macular degeneration.
“Dr. Rohrer is an addition of incredible value to our advisory team.” said Ichor CEO Kelsey Moody. “Her experience in the space will enable us to robustly and properly assess the effectiveness of our therapeutics in pre-clinical animal models.”
Dr. Rohrer brings over 20 years of ophthalmology research and teaching experience. She joins Ichor’s scientific advisory board in addition to her existing positions at the Medical University of South Carolina. With her participation in over 30 peer-reviewed publications between 2009 and 2014, and her own lab being dedicated to investigating the mechanism of photoreceptor degeneration and neuroprotection, Dr. Rohrer is a natural fit with Ichor, who have been working diligently on treatments for age-related macular degeneration since 2014.
Dr. Rohrer is currently a professor in the department of Graduate Studies and the Department of Ophthalmology, as well as the Stanley H. & Theodora L. Feldberg Professor Endowed Chair of the Department of Ophthalmology at the Medical University of South Carolina.
Ichor’s AMD research is a continuation of research started at the SENS Foundation, focusing on equipping exogenous enzymes known to degrade A2E with lysosomal targeting motifs to assess the utility of an enzyme augmentation therapy using a variety of in vitro and in vivo assays. Always interested in collaborating with other leaders in the field of Ophthalmology, Ichor looks forward to Dr. Rohrer’s guidance and the insights she brings with her from her many years of teaching and research experience.
Dr. Rohrer joins Gerold Feuer, Ph.D., Chief Science Officer at HuMurine Technologies, Inc., Robert Doyle, Ph.D., Professor of Chemistry at Syracuse University, Aubrey De Grey, Ph.D., Chief Science Officer at the SENS Foundation, and others already on our Scientific Advisory Board.